• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    10/3/23 9:06:12 AM ET
    $ACXP
    $ALXO
    $ICU
    $KA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email

    Gainers

    • ALX Oncology Holdings (NASDAQ:ALXO) stock increased by 96.2% to $9.44 during Tuesday's pre-market session. The company's market cap stands at $388.4 million.
    • POINT Biopharma Global (NASDAQ:PNT) shares increased by 84.14% to $12.31. The market value of their outstanding shares is at $1.3 billion.
    • SeaStar Medical Holding (NASDAQ:ICU) shares increased by 46.93% to $0.61. The company's market cap stands at $11.9 million.
    • MSP Recovery (NASDAQ:LIFW) stock increased by 18.44% to $0.24. The market value of their outstanding shares is at $78.5 million.
    • Kineta (NASDAQ:KA) stock rose 16.92% to $5.25. The company's market cap stands at $51.2 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares moved upwards by 15.29% to $0.52. The company's market cap stands at $3.0 million.

    Losers

    • MAIA Biotechnology (AMEX:MAIA) stock decreased by 23.2% to $1.95 during Tuesday's pre-market session. The market value of their outstanding shares is at $26.6 million.
    • SmileDirectClub (NASDAQ:SDC) stock decreased by 19.5% to $0.13. The company's market cap stands at $17.3 million.
    • OpGen (NASDAQ:OPGN) shares fell 19.05% to $0.34. The market value of their outstanding shares is at $3.0 million.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) shares declined by 14.19% to $1.21. The market value of their outstanding shares is at $15.7 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock decreased by 11.63% to $1.14. The market value of their outstanding shares is at $4.1 million.
    • RVL Pharmaceuticals (NASDAQ:RVLP) shares fell 10.79% to $0.11. The market value of their outstanding shares is at $12.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $ALXO
    $ICU
    $KA

    CompanyDatePrice TargetRatingAnalyst
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2026$6.00Buy
    UBS
    ALX Oncology Holdings Inc.
    $ALXO
    11/13/2025$4.00Buy
    Jefferies
    ALX Oncology Holdings Inc.
    $ALXO
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    ALX Oncology Holdings Inc.
    $ALXO
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    ALX Oncology Holdings Inc.
    $ALXO
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    ALX Oncology Holdings Inc.
    $ALXO
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    POINT Biopharma Global Inc.
    $PNT
    7/20/2023$12.00 → $14.00Buy
    Jefferies
    POINT Biopharma Global Inc.
    $PNT
    12/14/2022$10.00Outperform
    Raymond James
    More analyst ratings

    $ACXP
    $ALXO
    $ICU
    $KA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on ALX Oncology with a new price target

    UBS resumed coverage of ALX Oncology with a rating of Buy and set a new price target of $6.00

    3/6/26 8:38:03 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on ALX Oncology with a new price target

    Jefferies initiated coverage of ALX Oncology with a rating of Buy and set a new price target of $4.00

    11/13/25 9:09:54 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology upgraded by Jefferies with a new price target

    Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously

    3/6/25 7:17:16 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $ICU
    $KA
    SEC Filings

    View All

    SEC Form 10-K filed by ALX Oncology Holdings Inc.

    10-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

    3/9/26 4:03:57 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    3/9/26 8:59:44 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    3/5/26 9:00:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $ICU
    $KA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Klencke Barbara

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:05:06 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Klencke Barbara claimed ownership of 120,000 shares (SEC Form 3)

    3 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    3/5/26 4:01:03 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE AND CAO Pinto Shelly sold $1,283 worth of shares (565 units at $2.27), decreasing direct ownership by 0.64% to 87,708 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/20/26 4:01:02 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $ICU
    $KA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

    DENVER, March 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will participate in a fireside CEO chat with David Bautz, Senior Biotech Analyst at Zacks Small-Cap Research, at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 11, 2026. DATE: March 11th TIME: 12:00 pm E.T. REGISTER HERE Available for 1x1 meetings: March 11. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offe

    3/9/26 8:35:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

    Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical TrialsAcurx is launching a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to oneWhen coupled with IBZ Phase 2 results of being highly effective (96% clinical cure of 26 patients) in treating acute CDI with no recurrence in patients while sparing the gut microbiome, this new trial will position IBZ as a candidate to be the first agent to demonstrate clinical success in both the treatment of CDI and the prevention of rCDIIn a Phase 2 trial, all

    3/9/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $ICU
    $KA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goodman Corey S bought $4,999,999 worth of shares (3,184,713 units at $1.57) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    2/4/26 4:15:59 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $9,959 worth of shares (2,700 units at $3.69) and received a gift of 20,000 shares (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    1/12/26 8:44:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $69,999 worth of shares (57,189 units at $1.22) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:18:50 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $ICU
    $KA
    Leadership Updates

    Live Leadership Updates

    View All

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

    Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company's Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Kl

    9/12/25 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $ICU
    $KA
    Financials

    Live finance-specific insights

    View All

    ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers - - Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Canc

    2/27/26 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release. Fourth Quarter and Full Year 2025 Results Webcast Information Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET Webcast Access: https://viavid.webcasts.com/starthere.

    2/19/26 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                           Friday, March 13, 2026  Time:                     

    2/16/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ALXO
    $ICU
    $KA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 6:58:27 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care